Last reviewed · How we verify
SPN-817
At a glance
| Generic name | SPN-817 |
|---|---|
| Also known as | (-)-Huperzine A extended-release |
| Sponsor | Supernus Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures (PHASE2)
- RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures (PHASE2)
- Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy (PHASE2)
- Evaluating the Safety and Relative Bioavailability of Three SPN-817 Treatments (A, B and C) in Healthy Adult Subjects (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |